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Introduction 
The field of mechanical circulatory support is rapidly evolving and new data are 
published at a rate that can be overwhelming. Last year, we published a review 
paper entitled “What Did We Learn about VADs in 2014?” That paper was well 
received – the full text was downloaded over 350 times by the readers around 
the globe. Encouraged by this, we wrote the present review, where, like before, 
we summarized some of the publications from 2015 that we think are particularly 
important.  
Readers who wish to supplement this review or to argue with the author’s 
statements or article selection are encouraged to do so on our Facebook page at 
https://www.facebook.com/TheVADJournal. 
HeartMate III 
Perhaps the biggest news this year was the first clinical information on 
Heartmate III (HMIII) (St. Jude Medical, Pleasanton, California) which already 
received the Conformité Européene (CE) Mark approval in Europe for advanced 
heart failure patients, both as bridge to transplantation or as destination therapy.    
The HMIII is an intrapericardial centrifugal-flow pump with a magnetically 
levitated rotor. This design eliminates the need for mechanical bearings. 
Because the rotor is “floating”, the gaps through which the blood flows are wide 
(0.5-1 mm), to minimize  both blood stasis and shear stress to the blood. The 
new features are addressing all the adverse effects of currently used devices, 
including lack of pulsatility resulting in gastrointestinal bleeding (GIB) and aortic 
insufficiency, high shear stress leading to hemolysis and acquired von Willebrand 
syndrome, heat generation prompting pump thrombosis, and the driveline design 
precluding its replacement in case of damage (Figure 1). 
In summary, major novel features of HMIII are (1): 
 Intrapericardial position 
 Fully magnetically levitated rotor 
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 Rotor speed range of 3, 000 to 9,000 revolutions per minute 
(rpms) 
 Maximum flow rate of 10 L/min 
 No friction, heat generation, wear and tear 
 Wide gaps for the blood flow (blood flow paths) through the device 
(10-20 times wider than in currently used pumps) 
 Pump  speed change 30 times per minute to create pulsatility 
 External portion of the driveline can be changed without pump 
exchange 
 Texturing of the internal surface with titanium microspheres 
    These features are designed to achieve following effects: 
 Minimization of blood stasis 
 Minimization of shear stress to blood 
 Development of a pseudo-intima on the inside of the pump to 
prevent pump thrombosis 
 Maximizing of the aortic valve opening 
 
Figure 1. HeartMate III 
Reproduced from Scmitto et al. (2), with permission 
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The chest radiograph with HMIII is shown on Figure 2.  
 
 
Figure 2. Chest radiograph with HMIII 
Reproduced from Scmitto et al. (2), with permission 
The single-arm, prospective, multicenter study, designed to evaluate the 
performance and safety of the HMIII, enrolled 50 patients who received the LVAD 
as a bridge to transplant or as destination therapy. The primary endpoint was 6-
month survival compared with Interagency Registry for Mechanically Assisted 
Circulatory Support (INTERMACS). 
The 6 month survival was 92%, with 88% of patients continuing on support and 
4% transplanted, which exceeded the 88% performance goal. Major adverse 
events included re-operation for bleeding (14%), driveline infection (10%), 
gastrointestinal bleeding (8%), and debilitating stroke (8%). There were no pump 
exchanges, pump malfunctions, pump thrombosis, or hemolysis events. Overall 
stroke rate was 12% which was higher than expected  (3), and infection rate 36% 
(1). 
Outcomes 
The seventh  annual report of the INTERMACS summarized the data on 15,000 
patients, up from 10,000 last year, from 158 participating hospitals, and the 
number of implants of nearly 2,500 a year, roughly half of that as destination 
therapy. Noteworthy, the freedom from the adverse events is not improving (4). 
This may mean that the peak benefit that can be obtained from the current 
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technology, is already achieved, and further improvement should occur with 
major technological breakthroughs. Hopefully, HMIII is one of them.   
Putting the first outcomes with HMIII in the context of other continuous flow 
devices and the INTERMACS survival rates, the current survival is shown on 
Figure 3. 
 
Figure 3. Progressive improvement in outcomes with LVADs 
Reproduced from Uriel et al.(3), with permission 
Important information about the outcomes of less sick LVAD candidates on 
mechanical circulatory support versus medical management was obtained from 
the ROADMAP (Risk Assessment and Comparative Effectiveness of Left 
Ventricular Assist Device  and Medical Management). This was a prospective, 
multicenter  observational study of 200 patients (97 LVAD, 103 medical 
management) who had at least one hospitalization for HF in the last year and 
walked less than 300 m on 6-min walk, i.e. were functionally limited but not 
inotrope-dependent. Currently, such patients can be managed medically, but are 
also eligible for LVAD, depending largely on their own and their doctor’s 
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preferences. According to these preferences, they either underwent an LVAD 
implant, or continued on medical management. Although LVAD patients were 
sicker at baseline, the primary endpoint - survival with improvement in 6 minute 
walk distance by more than  75 m at 12 months – was achieved by 39% patients 
on LVADs versus 21% on medical management (OR 2.4   p = 0.012).  Survival 
per se was also greater for LVAD versus medical management (80 ± 4% vs. 63 ± 
5%; p = 0.022). Even despite more hospitalizations on LVADs, mostly for GI 
bleedings, quality of life improved greater than in the medical arm. (5).  
Basically, this study means, that many INTERMACS class IV patients, or the first 
class of patients which are not inotrope dependent, can benefit from the LVAD. 
In terms of ventricular recovery, there was even less enthusiasm in 2015 than 
before. The query of the UNOS registry of patients on long-term continuous-
flow LVADs, explant due to recovery was done in 5% of patients (34 out of 594), 
mostly young and non-ischemic. In the first year, one third of these patients 
either died or had heart transplant, therefore bringing the rate of true recovery 
down to slightly over 3% (6). In fact, this still represents an overestimation, 
because some patients will need re-implant of the LVAD, or cardiac 
transplantation, more than one year after the explant.  
LVAD-related physiology 
In 2015, several important contributions were made in terms of changes in the 
body that occur on LVAD support.  
Cognitive function improves after LVAD (7). On the contrary, sexual activity is 
reduced, as well as satisfaction with sex. Surprisingly, pulmonary function tests, 
including  forced expiratory volume in one second, forced vital capacity, and 
diffusing capacity for carbon monoxide deteriorated after LVAD implant (8).  
All the above studies were done on relatively small number of patients and 
should not discourage other group from re-addressing the same questions. 
Exercise physiology on LVAD 
The exercise physiology in LVAD recipients is not well known. Several studies in 
2015 were dedicated to this topic.  
In one study, patients with a swan-ganz catheter exercised on a supine bicycle, 
either at a fixed pump speed, or with progressive pump speed increase  
It appeared, that while at rest, increase in pump speed resulted in 18.8% 
increase in the blood flow, and decrease in pulmonary capillary wedge pressure, 
roughly from 14 to 9 mmHg. With exercise, the flow also increased, but so did 
the filling pressures, bringing the wedge pressure up to 25 mmHg, and right 
atrial pressure to 17 mmHg. Concomitant increase in pump speed did not 
alleviate this effect. The concentration of lactate and B type natriuretic peptide 
increased as well (9). 
 
For comparison, healthy people usually experience some increase in pulmonary 
capillary wedge pressure after the beginning of the exercise, but the wedge 
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decreases, although not to the baseline, and typically stays around 15 mmHg 
(10). 
 Also, the cardiopulmonary stress test, performed in 6 months after the LVAD 
implantation, showed that peak oxygen consumption improves somewhat from 
pre-LVAD level (11.6 ± 5.0 to 15.4 ± 3.9 ml/kg/min, P=0.009)., but never reaches 
normal values (11).  
The findings explain why LVAD patients almost always have some limitation of 
the activity. An extensive review on exercise physiology in LVAD recipients was 
published by Jung et al. (12) 
Candidate selection 
Obesity 
Over and over, obesity (body mass index ≥30 kg/m2) is proven not to be a 
contraindication for  LVAD implant (13). Obese patients had similar survival to 
non-obese, although they had more HF readmissions after the LVAD (OR 2.47, 
95% CI 1.15-5.32; P =0.02). The difference lost significance after adjustment for 
covariates (14). 
There is also a growing acceptance of surgical options for obesity treatment in 
LVADs. Last year, there was a report of successful sleeve gastrectomy in 
patients with LVAD. The surgery allowed them to lose weight and become 
transplant candidates (15). This year, Shah et al. (16) reported same procedure 
performed simultaneously with LVAD implant.   
Adult Congenital Disease 
One of the most challenging tasks in cardiology is caring for adults with complex 
congenital heart defects.  A case series of 5 patients (17) and a separate case 
report (18)  last year described successful use of LVAD on systemic right 
ventricle in adult patients with d-transposition of great arteries after an atrial 
switch procedure. The time on support was over a year in one case and a mean 
of 284 ± 177 days in the series. In total, 4 out of 6 patients underwent heart 
transplant. 
Management of patients on LVAD support 
Blood pressure measurement 
The group from Columbia University addressed a very practical and very 
important question about blood pressure measurement in patients with 
continuous flow LVADs. Because elevated blood pressure is associated with 
stroke (19), it is very important to know whether you are dealing with systolic or 
mean blood pressure. 
Obtaining blood pressure measurements via arterial line, Doppler, or standard 
automated cuff, the authors observed that if at least two out of three 
measurements by automated cuff were achieved (meaning that some pulsatility 
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was present), the blood pressure was measured more accurately than with the 
Doppler which tended to overestimate mean pressure (20).   
Ramp study 
In 2015, Uriel et al. (21) demonstrated that the ramp test guided by invasive 
hemodynamic measurement, results in better optimization of the LVAD function, 
than traditional echo-guided approach. They found that only 42.9% 
of patients had normal central venous and pulmonary capillary wedge pressure 
at their original settings. With the pump going from low to high speed in HMII 
recipients, cardiac output improved by 0.16 ± 0.19 L/min/step (total change 1.28 
± 1.41 L/min) and pulmonary capillary wedge pressure decreased by 1.23 ± 0.85 
mm Hg/step (total change 9.9 ± 6.5 mm Hg). Each step was 400 rpms. Central 
venous pressure and systolic blood pressure did not change. In over half of the 
patients (56%), they managed to approach near normal filling pressures. 
Increases in device speed were associated with increases in pulmonary artery 
oxygen saturations indicative of improved cardiac output. 
In patients with Heartware (HeartWare Corp., Framingham, Massachusetts), 
cardiac output increased by an average 0.09 L/min for each 100 rpm. In HMII, 
there was an increment of 0.2 L/min for each 400 rpms., with a trend to decrease 
in central venous pressure. Overall, increases in the pump speed were made in 
one third of the patients. 
Another important contribution was made by Adatya et al. (22). They showed that 
blunted response of the left ventricular size to aggressive unloading with 
increasingly high pump speed may result not only from pump thrombosis but 
from increased afterload: aortic regurgitation or systemic hypertension with mean 
arterial pressure over 85 mmHg. Both conditions would make it difficult to unload 
the LV. Practically, it means that positive ramp study should be used for 
confirmation of pump thrombosis only in the presence of elevated 
lactatedehydrogenase (LDH), as a sign of hemolysis. 
Pulmonary hypertension 
It is generally thought that pulmonary hypertension resolves after LVAD, but the 
timing is not established. Studying patients who had serial right heart 
catheterizations before and after LVAD implant, Houston et al. (23)  found that 
patients with reactive pulmonary hypertension (>3.5 Wood units) may still have 
high pulmonary vascular resistance even after 6 months of being on LVAD, and if 
transplant is considered, repeat right heart catheterization is justified. However, if 
reactive pulmonary hypertension was not present before the LVAD, there is no 
need to repeat right heart catheterization while the patients are on LVAD support, 
even if they need to be listed for heart transplant.   
Arrhythmias 
There are still no clear results showing how to manage arrhythmias in patients 
with LVADs. Lee et al.  (24) found only marginal benefit of automated implantable 
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cardioverters-defibrillators for survival. In their experience with a small (100 
patients) sample there were no deaths attributable to ventricular tachycardia, 
directly (sudden arrhythmic death) or indirectly (right ventricular failure induced 
by frequent arrhythmic episodes), but 43% of patients experienced defibrillator 
shocks, sometimes inappropriate. 
Ablation for VT in patients with LVADs is not such a rare procedure. A series of 
39 ablations in 34 patients with good success rate indicated that about two thirds 
of tachycardias were related to intrinsic myocardial scar, and only one third to the 
inflow cannula (25)   
A meta-analysis of observational studies confirmed that post-LVAD ventricular 
arrhythmias were associated with increased risk of all-
cause mortality after adjusting for competing risk factors at 60 days (OR 1.91, 
95%  CI  1.18 to 3.11, p = 0.001), 120 days ( OR 1.97, 95% CI 1.01 to 3.85, p = 
0.05), and 180 days (adjusted OR 2.04, 95% CI 1.01 to 4.15, p = 0.05) (26).  
Because almost all individual studies, selected for this meta-analysis, report 
worse outcomes in patients with ventricular arrhythmias, such results were quite 
predictable. 
LVAD and valves 
Tricuspid valve 
The issue of concomitant tricuspid valve repair during the LVAD implant in 
patients with more than mild tricuspid regurgitation is still controversial. This year, 
a propensity-matched group comparison indicated that such repair did not make 
difference in one year survival, need for re-thoracotomy, or early and late right 
heart failure and hepatic or renal failure.(33) 
 Aortic valve 
Severe aortic insufficiency carries substantial morbidity and mortality in LVAD 
patients. Treatment options include  transcatheter  closure using an Amplatzer 
Multi-Fenestrated Septal Occluder "Cribriform" device.  In a series of 10 patients, 
technical success was achieved in all patients, but only three (30%) survived six 
months (34). 
  
LVAD and kidneys 
Several good reviews were published this year. The first of them (27) is 
dedicated to kidney issues and LVADs in general. Importantly, it analyzes in 
detail the dynamic changes in renal function after LVAD implant depending on 
the baseline (pre-LVAD) glomerular filtration rate. Originally, this was reported by 
Brisco et al. (28). Although renal function, after initial improvement, deteriorates 
on LVAD support in patients with lower baseline glomerular filtration rate, the 
function is still better than before the implant (Figure 4) 
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Three other reviews specifically discuss the issues of hemodialysis in patients on 
LVAD support, including access, blood pressure management, infection risks, 
etc.(29-32)  . 
 
 
 
Figure 4. Dynamic changes in kidney function after LVAD implant, stratified 
by the pre-implant glomerular filtration rate.  
Reproduced from Brisco et al.(28), with permission 
 
Anticoagulation in VADs 
Like in 2014, the topics of anticoagulation and pump thrombosis were in the 
spotlight last year. While the management of these aspects are still mostly 
empiric, number of studies added some evidence. The initiation of 
anticoagulation in the post-operative period after LVAD implant was studied in 
the non-interventional, retrospective, matched historical control cohort study. All 
patients were started on aspirin 325 mg after the hemostasis was achieved. 
Patients bridged to warfarin with intravenous heparin, intravenous bivalirudin, or 
not bridged were compared in terms of thromboembolic and bleeding 
complications up to 30 days post implant. Thromboembolism was significantly 
lower on heparin versus no bridging (4.9% vs. 27.0%, p = 0.008). Heparin was 
also associated with increased risk of bleeding in a multivariate analysis (OR 
2.93, 95% CI 1.15-7.43). Bivalirudin was no different from no bridging. It appears 
that bridging with heparin was the most effective regimen to prevent 
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thromboembolic events, but at the cost of higher bleeding risk. The median time 
to starting parenteral bridge therapy was 2 days post-LVAD implantation  (35). 
Regarding antithrombotic management, Jorde’s group from Montefiore 
retrospectively compared three regimens, concomitantly with warfarin, in patients 
on HMII: 
 ASA 81 mg+dipyridamole 75 mg, target INR 2 to 3 
 ASA 81 mg, target INR 1.5 to 2 
 ASA 325 mg, target INR 2 to 3 
With similar rates of thrombotic events, bleeding episodes almost tripled on high 
dose aspirin. From this study, the 81 mg a day dose of ASA is sufficient for HMII 
recipients, and the dose of 325 mg/day increases the bleeding risk without 
adding the antithrombotic benefit.(36)   
Safety of reduced anti-thrombotic therapy in HMII recipients, most of which had a 
bleeding event on LVAD support, was explored in the TRACE U.S. (STudy of 
Reduced Anti-Coagulation/Anti-platelEt Therapy in Patients with the HeartMate II 
LVAS). This was a multicenter, prospective and retrospective, observational 
study. 
The enrolled 100 participants were outpatients on a regimen of reduced anti-
thrombotic therapy, defined as warfarin only (38%), aspirin only (28%), or no anti-
thrombotic agent (34%). Freedom from ischemic stroke at 1 year was 93.8% ± 
2.5%, and freedom from device thrombosis was 92.7% ± 2.7%. Despite reduced 
anticoagulation and antithrombotics, a subsequent bleeding event occurred in 
52%, although there were no intracerebral bleeds. There was no comparison of 
strategies against each other (51). 
Another open question in the area of anticoagulation in LVADs is optimal 
monitoring when patients are on intravenous heparin, for bridging to therapeutic 
INR or for pump thrombosis. Adatya et al. (37) compared anti-Xa factor and 
activated thrombin time (aPTT) and found disturbingly high discordance in paired 
blood samples. The results of the two assays were considered concordant if they 
both indicated that anticoagulation was within therapeutic, subtherapeutic, or 
supratherapeutic range. The discordance was 63.8% in the bridging cohort and 
84.2% in the pump thrombosis cohort, where therapeutic level of anticoagulation 
is critically important. The most common pattern of discordance was a 
supratherapeutic aPTT value and a therapeutic anti-Xa level (49.1% for bridging 
vs. 75.8% for device obstruction; p < 0.001), likely because hemolysis per se, as 
well as elevated INR, which was frequent in these patients, can prolong aPTT.  
Anti-Xa assay may therefore give a more accurate guidance on heparin 
concentration in this population (37). 
Complications of the VADs 
HeartMate II versus Heartware 
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In a single institution experience with these two devices, mortality was similar, as 
well as GI bleeding or pump thrombosis.  The time-related cumulative risk of any 
infection was significantly higher with the HVAD, but the rate of driveline infection 
was similar. The risk of stroke was higher with Heartware (HR: 1.8,(1.25, 2.5), P 
= 0.003), with the difference being driven by hemorrhagic stroke (39). 
Pump thrombosis 
Histologic analysis of clots in explanted axial continuous-flow LVADs revealed 2 
distinct clot varieties. The young clot, found in acute pump failure, was primarily 
seen around the inlet and outlet stators. It was composed of serum proteins 
mixed with fibrin and red blood cells breakdown products. The more chronic clot 
variety had more fibrin layering with more erythrocyte breakdown products and 
small amount of cellular infiltrate, and it was found mostly on the rotor.  This kind 
of clot is likely originates from the heat due to friction on the bearings. Such clot 
may cause partial obstruction of the device with subsequent increase of 
hemolysis/shear stress and propagating of the clot via platelet activation. (40) 
The summary of data on pump thrombosis in different cohorts was published by 
Stewart et al. (41) (Figure 5) 
 
Figure 5. Incidence of pump thrombosis. Reproduced from Stewart et al, (41), 
with permission. 
According to the INTERMACS data, the growing rate of pump thrombosis began 
in 2010, reached a maximum in 2012, and then plateaued at a level that was 3.3-
times higher than pre-2010 (42). There was some decrease during the first half of 
2014. It appears from the graph on Figure 6, the peak of pump thrombosis 
occurs within first three months after the LVAD implant, underscoring the 
importance of early anticoagulation. 
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Risk factors for pump thrombosis included younger age (p < 0.001), higher body 
mass index (p = 0.02), history of non-compliance (p = 0.004), severe right heart 
failure (p = 0.02), later date of implant (p < 0.0001), and elevated LDH during the 
first month post-implant (p < 0.0001). Subsequent pump thrombosis was more 
likely if the initial pump exchange indication was pump thrombosis (p < 0.0001).  
After the pump exchange for thrombosis, the 1 year mortality was high at 30% 
(43). Also, erythropoietin in LVAD patients was clearly associated with higher 
rate of pump thrombosis (52). 
 
Figure 6. Rate of pump thrombosis up to 1 year post implant, by the year of 
implant. Reproduced from Kirklin et al. (43), with permission. 
While there is no further increase in the rate of pump thrombosis, some centers 
report this complication in up to 20% of patients (44). Last year, several 
publications discouraged medical treatment of this complication, favoring early 
pump exchange (45,46).  In 2015, once again, there were several papers 
comparing different strategies in treatment of pump thrombosis. 
In one of the studies, medical therapy with intravenous heparin, antiplatelet 
agents, antithrombotic agents, or thrombolytics led to resolution of hemolysis, 
and discharge to home, in 15 of 25 (60%) cases; however, this strategy was 
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associated with intracranial hemorrhage in 4 patients and readmission with 
recurrent thrombosis in 10 patients.   
Specifically, neither unfractionated heparin nor bivalirudin reliably resolved 
thrombosis in the patients where these agents were used as a first line therapy. 
Primary therapy with eptifibatide, was successful in one of four patients (25%). 
Alteplase, added on top of one or more agents, resulted in 50% success, one 
recurrence, and one intracerebral bleeding. LVAD exchange, predictably, 
provided better results (44). 
In patients with Heartware, initial medical treatment was successful in 48% 
ofcases, while surgery was successful in all cases (47). Pump exchange still 
appears the safest option when dealing with pump thrombosis. 
In the 2014 review, we included the innovative report from the Berlin group (48) 
about the use of acoustic characteristics of the working pump for diagnostics of 
pump thrombosis (Heartware). In 2015, there was a further development of this 
topic. An electronic stethoscope was used to record sounds from HMII. The data 
were then uploaded to a computer and analyzed. Device thrombosis was found 
to be associated with reduced LVAD acoustic amplitude in two patients who 
underwent surgical device exchange (49). 
A novel method of diagnosis of pump thrombosis and of successful treatment 
with thrombolytics using the log files of the Heartware pump was suggested by 
Jorde et al. (50). The growth rate and percent of expected power were the log file 
parameters associated with successful treatments   
Gastrointestinal Bleeding 
In 2015, the nature of LVAD-related coagulopathy was further investigated. 
Exposure of blood from healthy people to LVAD resulted in rapid decrease of the 
level of von Willebrand factor in general, and high molecular weight multimers in 
particularly. This demonstrated the role of the cleavage protein ADAMTS-13 in 
the process, because no similar depletion occurred when the blood was taken 
from patients with congenital deficiency of ADMTS-13. Additionally, when 
platelets were removed from normal blood, no depletion occurred despite same 
shear stress. Hence, sheer stress, ADAMTS-13, and dysfunctional platelets with 
abnormal aggregation are all essential in the development of LVAD related 
coagulopathy (53). 
 Inhibition of ADAMTS-13 may be therefore considered a therapeutic target to 
reduce degradation of von Willebrand factor resulting from shear stress. One of 
the drugs inhibiting ADAMTS 13 is doxycycline. In vitro, doxycycline (5 
mg/dl) decreased ADAMTS-13 activity and protected multimers of von Willebrand 
factor. Because usual therapeutic dose of doxycycline normally produces plasma 
levels of 0.3 to 0.5 mg/dl, or 10 times lower than in the study, clinical application 
of this finding is so far uncertain (54). 
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In one retrospective study, severe RV dysfunction was identified as a risk factor 
for GI bleeding ( HR 1.799, 95% CI: 1.089 to 2.973, p = 0.022). Because 
coagulation parameters, antithrombotic regimens, and flow pulsatility/aortic valve 
opening were no different in patients with and without RV dysfunction, liver 
congestion or decreased pulsatility due to severe RV dysfunction did not explain 
the difference. Congestion in mesenteric circulation was proposed by the author 
as a hypothesis explaining this phenomenon.(55) 
 Infections in LVADs 
Once again, there was strong evidence to support leaving the entire velour 
portion of the driveline below the skin – this technique was associated with 50% 
reduction in driveline infection compared with results from the HMII destination 
therapy trial.(57) Also, there were reports from individual centers about their 
strategies to curb the driveline infection (58).  
Early post-operation ileus 
Ileus can be a problem early after the surgery. In order to decrease postoperative 
ileus, an aggressive bowel regimen was used with good results: clear liquids until 
first bowel movement, then full liquids until the second bowel movement, then 
advancing the diet. Docusate was given on postoperative day 1 and bisacodyl 
rectally on the second day, and the enema was added if ileus developed. The 
goal was a bowel movement every 2 days, with enemas and polyethylene glycol 
given daily as needed. The incidence of ileus was 4%, a dramatic decrease 
comparing with less aggressive protocol (38).   
Various pumps 
Several interesting new pumps were introduced or further developed in 2015.  
Impella 
Although this pump is not new, the data about it, published in 2015, were quite 
interesting. Many of us empirically know that hemolysis is a frequent complication 
on Impella support, but for the first time as high rate as 62.3%  (60) reported 
when the device was in use for more than 6 hours, which is typical when it is 
inserted for treatment of cardiogenic shock rather than protection during high risk 
percutaneous coronary intervention. Such a high rate raises concern of utility of 
this pump for the purpose of hemodynamic support. The average time of support 
was 86.63 hours.  After 24 hours of support, the hemoglobin decreased 
significantly despite 17% of patients receiving blood transfusion (p = 0.0001). By 
the time of removal, 65% of patients were transfused to maintain a hemoglobin of 
10 mg/dL (p = 0.0014). The LDH increased to 5,201 U/L (n = 22; p = 0.0096), the 
bilirubin to 5.6 mg/dL (p = 0.008), and the haptoglobin level was 15.4 mg/dL (n = 
25).     
Impella for RV support 
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Last year, we mentioned the study The RECOVER RIGHT, unpublished at that 
time, as a basis for the FDA approval of right sided Impella. In January of 2015, 
the FDA approved a percutaneous right-sided Impella PR (right peripheral; 
Abiomed, Danvers, MA) for 14 days of support for right ventricular failure under a 
humanitarian device exemption (Figure 6 in our review “What did we learn about 
LVADs in 2014?”). Now this prospective, open label, single arm, non-
randomized, multicenter study is published.  
This study included two cohorts in several American centers: 18 patients with 
RVF after left LVAD) implantation and 12 patients with RVF after cardiotomy or 
myocardial infarction. The primary end point was survival to 30 days or hospital 
discharge (whichever was longer). Implantation of the device resulted in 
immediate increase in cardiac index from 1.8 ± 0.2 to 3.3 ± 0.23 liters/min/m2 (p < 
0.001) and a decrease in central venous pressure from 19.2 ± 4 to 12.6 ± 1 mm 
Hg (p < 0.001). Average time on support was 3.0 ± 1.5 days (range, 0.5-7.8 
days). The overall survival at 30 days was 73.3%. All patients discharged were 
alive at 180 days (61). 
Historically, survival in similar patient population is less than 50% (62) 
A HeartWare MVAD (HeartWare, Inc., Miami Lakes, FL USA), is shown on 
Figure 7, 8 
This minipump weighs only 78 g compare with MMII -290 g, and Heartware – 160 
g). 
It can deliver up to 7L/min of flow. Implanted in 4 sheep, it demonstrated good 
performance. 
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Figure 7. The Heartware Minituarized LVAD (left) and Heartware device 
(right). Reproduced rom Cheung et al. (59), with permission 
 
 
 Figure 8. Heartware MVAD. Reproduced from Cheung et al. (59), with 
permission 
The Synergy Micro-pump 
The Synergy Micro-pump (The Synergy System, HeartWare Inc, Framingham, 
MA) is the smallest implantable LVAD that is currently available and can produce 
flows of up to 4.25 L/min.  In a simulation theoretical model, Burkoff et al.  (64) 
tested this device in HF with preserved LVEF. In this condition, regardless of the 
etiology, LV is usually not dilated and therefore not very suitable for implantation 
of an LVAD.  However, the LV end diastolic pressure is elevated, as well as left 
atrial pressure, and left atrium is typically enlarged. Decompressing the left 
atrium with the Synergy pump was hemodynamically beneficial.  
Symphony device 
A new partial support device was implanted with good outcome. The Symphony 
device (Abiomed, Danvers, MA) is a 30-mL stroke volume pump that is placed in 
the infraclavicular fossa (Figure 9). The pump is attached to the subclavian artery 
through a single short graft that functions as a bidirectional flow conduit. Pump 
filling occurs during ventricular systole, which provides afterload reduction. 
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During ventricular diastole, the pump ejects blood, which increases coronary and 
systemic blood flow (63) 
.  
 
 
Figure 9.  The Symphony device for partial support. Reproduced from Cecere 
et al. (63), with permission. 
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